Press Release

<< Back
View printer-friendly version

Spark Therapeutics to Participate in J.P. Morgan Healthcare Conference

PHILADELPHIA, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that Jeffrey D. Marrazzo, chief executive officer, will be presenting at 4:30 p.m. PT, on Monday, Jan. 7, at the Westin St. Francis Hotel, during the 37th Annual J.P. Morgan Healthcare Conference in San Francisco.

A webcast of Marrazzo’s presentation will be available live on www.sparktx.com on the "Events" section of the Investors page. A replay of the presentation will be available on the website for 90 days following the conference. To access the full presentation slide deck, please visit "Investor Presentations" on the Investors page.

About Spark Therapeutics
At Spark Therapeutics, a fully integrated, commercial company committed to discovering, developing and delivering gene therapies, we challenge the inevitability of genetic diseases, including blindness, hemophilia, lysosomal storage disorders and neurodegenerative diseases. We have successfully applied our technology in the first gene therapy for a genetic disease approved in the U.S. and EU and currently have three programs in clinical trials, including product candidates that have shown promising early results in patients with hemophilia. At Spark, we see the path to a world where no life is limited by genetic disease. For more information, visit www.sparktx.com, and follow us on Twitter and LinkedIn.

Investor Contact: Media Contact:  
Ryan Asay Monique da Silva  
Ryan.asay@sparktx.com communications@sparktx.com  
(215) 239-6424 (215) 282-7470  
     

Spark Therapeutics Logo

Source: Spark Therapeutics, Inc.